多发性硬化患者的COVID-19疫苗应答
结果显示抗CD20单抗和芬戈莫德显著降低血清转换率,其他药物与未治疗组无显著差异。疫苗类型可预测血清转换,但在抗CD20治疗者中无此效应。
要点
- 抗CD20单抗和芬戈莫德与MS患者接种SARS-CoV-2疫苗后血清转换降低相关
- 其他疾病修正治疗与未治疗组的血清转换无显著差异
- 40%血清阴性者仍可检测到抗SARS-CoV-2 T细胞应答
核心结论
- 部分疾病修正治疗增加MS患者SARS-CoV-2疫苗血清学应答减弱的风险。
主要发现
- 与未治疗相比,抗CD20单抗的血清转换比值比为0.03(95%CI 0.01-0.06,p<0.001)。
- 与未治疗相比,芬戈莫德的血清转换比值比为0.04(95%CI 0.01-0.12)。
- 其他药物与未治疗组的血清转换无显著差异。
- 距末次抗CD20治疗时间和总治疗时间均与疫苗应答显著相关。
- 疫苗类型显著预测血清转换,但在抗CD20治疗者中无此效应。
临床怎么用
- 对使用抗CD20单抗或芬戈莫德的MS患者,应关注SARS-CoV-2疫苗血清学应答可能减弱。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines in people with multiple sclerosis (MS). METHODS: Four hundred seventy-three people with MS provided one or more dried blood spot samples. Information about coronavirus disease 2019 (COVID-19) and vaccine history, medical, and drug history were extracted from questionnaires and medical records. Dried blood spots were eluted and tested for antibodies to SARS-CoV-2. Antibody titers were partitioned into tertiles with people on no disease modifying therapy as a reference. We calculated the odds ratio of seroconversion (univariate logistic regression) and compared quantitative vaccine response (Kruskal Wallis) following the SARS-CoV-2 vaccine according to disease modifying therapy. We used regression modeling to explore the effect of vaccine timing, treatment duration, age, vaccine type, and lymphocyte count on vaccine response. RESULTS: Compared to no disease modifying therapy, the use of anti-CD20 monoclonal antibodies (odds ratio = 0.03, 95% confidence interval [CI] = 0.01-0.06, p < 0.001) and fingolimod (odds ratio = 0.04; 95% CI = 0.01-0.12) were associated with lower seroconversion following the SARS-CoV-2 vaccine. All other drugs did not differ significantly from the untreated cohort. Both time since last anti-CD20 treatment and total time on treatment were significantly associated with the response to the vaccination. The vaccine type significantly predicted seroconversion, but not in those on anti-CD20 medications. Preliminary data on cellular T-cell immunity showed 40% of seronegative subjects had measurable anti-SARS-CoV-2 T cell responses. INTERPRETATION: Some disease modifying therapies convey risk of attenuated serological response to SARS-CoV-2 vaccination in people with MS. We provide recommendations for the practical management of this patient group. ANN NEUROL 20219999:n/a-n/a.
引用
- Tallantyre EC, Vickaryous N, Anderson V, et al. COVID-19 Vaccine Response in People with Multiple Sclerosis. Ann Neurol. 2021. PMID: 34687063. doi:10.1002/ana.26251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。